Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 466 to 480 of 887 results for score

  1. What is the effectiveness and safety of sacral nerve stimulation and transanal irrigation compared to symptomatic treatment for people with major low anterior resection syndrome?

    care. LARS should be assessed using a validated tool, for example the LARS score, which is a validated patient-administered...

  2. Electrotherapy for the treatment of haemorrhoids (HTG377)

    Evidence-based recommendations on electrotherapy for treating grade I to III haemorrhoids in adults. This involves using electric current to shrink the haemorrhoids.

  3. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  4. Targeted muscle reinnervation for managing limb amputation pain (HTG750)

    Evidence-based recommendations on targeted muscle reinnervation for managing limb amputation pain. This involves attaching nerves that were cut during limb amputation to other nerves in nearby muscles.

  5. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  6. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (TA1150)

    Evidence-based recommendations on encorafenib (Braftovi) plus binimetinib (Mektovi) for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer in adults.

  7. O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)

    NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .

  8. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

  9. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

  10. Dementia (QS184)

    This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.

  11. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

  12. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  13. Transcatheter aortic valve implantation for aortic stenosis (HTG446)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for aortic stenosis. This involves inserting a new valve through a catheter, usually by way of a large blood vessel at the top of the leg, into the heart and inside the existing faulty valve.

  14. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  15. Sinusitis (acute): antimicrobial prescribing (NG79)

    This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.